Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Reactions Skin Allergic reactions (sic) (~1%) Cellulitis Dermatitis (~1%) Diaper rash (~1%) Eczema (~1%) Erythema multiforme Herpes simplex (2001): Takayama N+, Pediatr Infect Dis J 20(2), 226 Herpes zoster (2003): Levin MJ+, JInfectDis188(7), 954 (2003): Naseri A+, Am J Ophthalmol 135(3), 415 (2002): Uebe B+, Eur J Pediatr 161(8), 442 (2000): Brunell PA+, Pediatrics 106(2), E28 (1999): Christensen CL+, Ugeskr Laeger 161(6), 794 (1989): Hammerschlag MR+, JInfectDis160(3), 535 (1988): Gershon AA+, JInfectDis158(1), 132 Impetigo Miliaria (~1%) Pruritus (~1%) Purpura (1986): Lee SY+, Am J Pediatr 8(1), 78 Rash (sic) (2005): Prescrire Int 14(77), 85 (2005): Quinlivan M+, JMedVirol75(1), 174 (2004): Quinlivan ML+, JInfectDis190(4), 793 (2000): Wise RP+, JAMA 284(10), 1271 (1986): Arbeter AM+, Pediatrics 78(4), 748 (1986): Gershon AA+, Pediatrics 78(4), 757 (in children with leukemia) (1985): Gershon AA+, Postgrad Med J 61, 73 (1984): Gershon AA+, JAMA 252(3), 355 (1984): Oka T+, Biken J 27, 2 Stevens–Johnson syndrome Urticaria (~1%) Vesiculation (2000): Sharrar RG+, Vaccine 19(7-8), 916 Xerosis (~1%) Eyes Intraocular pressure increased (2003): Naseri A+, Am J Ophthalmol 135(3), 415 Keratitis (2003): Naseri A+, Am J Ophthalmol 135(3), 415 Scleritis (2003): Naseri A+, Am J Ophthalmol 135(3), 415 Uveitis (2003): Naseri A+, Am J Ophthalmol 135(3), 415 Other Abdominal pain (~1%) Anaphylactoid reactions/Anaphylaxis (2000): Wise RP+, JAMA 284(10), 1271 Chills (~1%) Cough (~1%) Death (2000): Wise RP+, JAMA 284(10), 1271 Fever (15%) (2005): 15977369 OWN, Prescrire Int 14(77), 85 Injection-site edema (19%) Injection-site erythema (19%) Injection-site hematoma (19%) Injection-site induration (19%) Injection-site pain (19%) (2004): Kosuwon P+, Southeast Asian J Trop Med Public Health 35(3), 697 Injection-site pruritus (19%) Injection-site reactions (2005): Oxman MN+, NEnglJMed352(22), 2271 (2000): Wise RP+, JAMA 284(10), 1271 (1986): Arbeter AM+, Pediatrics 78(4), 748 Myalgia/Myositis/Myopathy/Myotoxicity (~1%) Upper respiratory infection (~1%) VASOPRESSIN Synonyms: ADH; antidiuretic hormone Trade names: Pitressin (Monarch); Pressyn Indications: Diabetes insipidus Category: Antidiuretic hormone Half-life: 10–20 minutes Reactions VASOPRESSIN 571 Skin Allergic reactions (sic) (
572 VECURONIUM VECURONIUM Trade names: Norcuron; Vecuron Indications: Adjunct to general anesthesia Category: Non-depolarizing neuromuscular blocker Half-life: 65–75 minutes Clinically important, potentially hazardous interactions with: aminoglycosides, betamethasone, cyclosporine, gentamicin, halothane, inhalational anesthetics, kanamycin, magnesium salts, neomycin, quinidine, streptomycin, succinylcholine, tobramycin Reactions Other Anaphylactoid reactions/Anaphylaxis (2005): Bhananker SM+, Anesth Analg 101(3), 819 (2005): Karila C+, Allergy 60(6), 828 (1994): Watkins J, Acta Anaesthesiol Scand Suppl 102, 6 (1993): Yagi T+, Masui 42(4), 598 (1990): Treuren BC+, Br J Anaesth 64(1), 125 (1988): Charlton SM, Anaesthesia 43(8), 707 (1988): Farrell AM+, Anaesthesia 43(3), 207 (1988): Holt AW+, Anaesth Intensive Care 16(3), 378 (1988): Thacker MA+, Anaesth Intensive Care 16(1), 129 Hypersensitivity (2004): Sanchez Palacios A+, Allergol Immunopathol (Madr) 32(6), 352 Injection-site pain (2003): Blunk JA+, Eur J Anaesthesiol 20(3), 245 (1998): Ti LK+, Br J Anaesth 81(3), 487 (1995): Chow LH+, Zhonghua Yi Xue Za Zhi 55(4), 315 (1988): Kent AP+, Anaesthesia 43(4), 334 Neurotoxicity (2001): Geller TJ+, Neuromuscul Disord 11(6-7), 579 VENLAFAXINE Trade name: Effexor (Wyeth) Indications: Depression Category: Antidepressant, bicyclic; Serotonin-norepinephrine reuptake inhibitor Half-life: 3–7 hours Clinically important, potentially hazardous interactions with: isocarboxazid, linezolid, MAO inhibitors, metoclopramide, phenelzine, selegiline, sibutramine, sumatriptan, tramadol, tranylcypromine, trazodone, trimipramine Reactions Skin Acne (
- Page 596 and 597: (2005): Fumal I+, Dermatology 210(3
- Page 598 and 599: (2000): Ernst E+, Forsch Komplement
- Page 600 and 601: Reactions Skin Allergic reactions (
- Page 602 and 603: Reactions Skin Diaphoresis (>1%) Ed
- Page 604 and 605: Mucosal Oral ulceration (1987): Hig
- Page 606 and 607: TETRACYCLINE Trade names: Apo-Tetra
- Page 608 and 609: Xerosis (2002): Bariol C+, J Gastro
- Page 610 and 611: Eyes Conjunctivitis (allergic conta
- Page 612 and 613: Other Anaphylactoid reactions/Anaph
- Page 614 and 615: (2000): Chemnitz JM+, Med Klin (Ger
- Page 616 and 617: Note: Cutaneous side-effects of bet
- Page 618 and 619: Other Cough (0.8%) Fever (4.6%) Hep
- Page 620 and 621: TOLAZAMIDE* Trade names: Diabewas;
- Page 622 and 623: Reactions Skin Erythema (1.9%) Fung
- Page 624 and 625: TOSITUMOMAB & IODINE 131 Trade name
- Page 626 and 627: (2001): Vogel CL+, Oncology 61, 37
- Page 628 and 629: (1997): Gilchrest BA, JAmAcadDermat
- Page 630 and 631: Erythema (1999): Alexiou C+, Laryng
- Page 632 and 633: *Note: Trichlormethiazide is a sulf
- Page 634 and 635: TRIMETHOPRIM* Trade names: Abaprim;
- Page 636 and 637: Myalgia/Myositis/Myopathy/Myotoxici
- Page 638 and 639: Other Death (2002): Avarello TP+, N
- Page 640 and 641: (2001): Pechlaner C+, Blood Coagul
- Page 642 and 643: Bullous dermatitis (2001): Christ E
- Page 644 and 645: (1985): Schifter S+, Lancet 2, 499
- Page 648 and 649: VERAPAMIL Trade names: APO-Verap; A
- Page 650 and 651: Mucosal Gingival hyperplasia/hypert
- Page 652 and 653: (2001): Laack E+, Ann Oncol 12(12),
- Page 654 and 655: Fixed eruption (
- Page 656 and 657: (1986): Sjoberg A+, Lakartidningen
- Page 658 and 659: (1990): Broder S+, Am J Med 88, 31S
- Page 660 and 661: (1989): Valencia ME+, Rev Clin Esp
- Page 662 and 663: ZOLPIDEM Trade names: Ambien (Sanof
- Page 664 and 665: DRUGS RESPONSIBLE FOR COMMON REACTI
- Page 666 and 667: Ethambutol Ethanolamine Etoposide F
- Page 668 and 669: Procarbazine Progestins Promethazin
- Page 670 and 671: Erlotinib Ertapenem Escitalopram Et
- Page 672 and 673: Feverfew Floxuridine Fluconazole Fl
- Page 674 and 675: Insulin glulisine Interferon alfa I
- Page 676 and 677: Acamprosate Acebutolol Acetaminophe
- Page 678 and 679: Amobarbital Amoxicillin Amphoterici
- Page 680 and 681: Spironolactone Streptomycin Sulface
- Page 682 and 683: Miconazole Midazolam Minocycline Mi
- Page 684 and 685: Heroin Hydralazine Hydrochlorothiaz
- Page 686 and 687: Nefazodone Nevirapine Niacin Nicoti
- Page 688 and 689: Mephenytoin Mercaptopurine Mesalami
- Page 690 and 691: Cephradine Cetuximab Chamomile Chlo
- Page 692 and 693: Oxaprozin Penicillin G Phenytoin Pi
- Page 694 and 695: Ritonavir Rofecoxib Saquinavir Sele
Reactions<br />
Skin<br />
Allergic reactions (sic) (~1%)<br />
Cellulitis<br />
Dermatitis (~1%)<br />
Diaper rash (~1%)<br />
Eczema (~1%)<br />
Erythema multiforme<br />
Herpes simplex<br />
(2001): Takayama N+, Pediatr Infect Dis J 20(2), 226<br />
Herpes zoster<br />
(2003): Levin MJ+, JInfectDis188(7), 954<br />
(2003): Naseri A+, Am J Ophthalmol 135(3), 415<br />
(2002): Uebe B+, Eur J Pediatr 161(8), 442<br />
(2000): Brunell PA+, Pediatrics 106(2), E28<br />
(1999): Christensen CL+, Ugeskr Laeger 161(6), 794<br />
(1989): Hammerschlag MR+, JInfectDis160(3), 535<br />
(1988): Gershon AA+, JInfectDis158(1), 132<br />
Impetigo<br />
Miliaria (~1%)<br />
Pruritus (~1%)<br />
Purpura<br />
(1986): Lee SY+, Am J Pediatr 8(1), 78<br />
Rash (sic)<br />
(2005): Prescrire Int 14(77), 85<br />
(2005): Quinlivan M+, JMedVirol75(1), 174<br />
(2004): Quinlivan ML+, JInfectDis190(4), 793<br />
(2000): Wise RP+, JAMA 284(10), 1271<br />
(1986): Arbeter AM+, Pediatrics 78(4), 748<br />
(1986): Gershon AA+, Pediatrics 78(4), 757 (in children with<br />
leukemia)<br />
(1985): Gershon AA+, Postgrad Med J 61, 73<br />
(1984): Gershon AA+, JAMA 252(3), 355<br />
(1984): Oka T+, Biken J 27, 2<br />
Stevens–Johnson syndrome<br />
Urticaria (~1%)<br />
Vesiculation<br />
(2000): Sharrar RG+, Vaccine 19(7-8), 916<br />
Xerosis (~1%)<br />
Eyes<br />
Intraocular pressure increased<br />
(2003): Naseri A+, Am J Ophthalmol 135(3), 415<br />
Keratitis<br />
(2003): Naseri A+, Am J Ophthalmol 135(3), 415<br />
Scleritis<br />
(2003): Naseri A+, Am J Ophthalmol 135(3), 415<br />
Uveitis<br />
(2003): Naseri A+, Am J Ophthalmol 135(3), 415<br />
Other<br />
Abdominal pain (~1%)<br />
Anaphylactoid reactions/Anaphylaxis<br />
(2000): Wise RP+, JAMA 284(10), 1271<br />
Chills (~1%)<br />
Cough (~1%)<br />
Death<br />
(2000): Wise RP+, JAMA 284(10), 1271<br />
Fever (15%)<br />
(2005): 15977369<br />
OWN, Prescrire Int 14(77), 85<br />
Injection-site edema (19%)<br />
Injection-site erythema (19%)<br />
Injection-site hematoma (19%)<br />
Injection-site induration (19%)<br />
Injection-site pain (19%)<br />
(2004): Kosuwon P+, Southeast Asian J Trop Med Public Health<br />
35(3), 697<br />
Injection-site pruritus (19%)<br />
Injection-site reactions<br />
(2005): Oxman MN+, NEnglJMed352(22), 2271<br />
(2000): Wise RP+, JAMA 284(10), 1271<br />
(1986): Arbeter AM+, Pediatrics 78(4), 748<br />
Myalgia/Myositis/Myopathy/Myotoxicity (~1%)<br />
Upper respiratory infection (~1%)<br />
VASOPRESSIN<br />
Synonyms: ADH; antidiuretic hormone<br />
Trade names: Pitressin (Monarch); Pressyn<br />
Indications: Diabetes insipidus<br />
Category: Antidiuretic hormone<br />
Half-life: 10–20 minutes<br />
Reactions<br />
VASOPRESSIN 571<br />
Skin<br />
Allergic reactions (sic) (
Change language